Sponsored Resources

APPs Bridging Science and Care: Understanding and Advocating for Bispecifics in Later Line Multiple Myeloma

August 25th 2025

For the First Time, A Nilotinib Without Fasting Restrictions

July 11th 2025

Promising Treatment To Raise the Standard of Care in Lower-Risk MDS-Related Anemia

May 30th 2025

Spectrum of HER2 expression: overview and clinical significance

October 1st 2024

Advancing Treatments in Resectable Non-Small Cell Lung Cancer

December 15th 2023

AmerisourceBergen: Investing in the future

November 1st 2022

The company is leaning even more into specialty drugs, with a new distribution center in California, and innovating to meet the changing needs of customers.

Higher-Risk MDS Satellite Symposium

May 20th 2022

Program chair Navel Daver, MD, invites you to PER®’s complimentary in-person and virtual satellite symposium.

Next-Gen SERDs in ER+/HER- Breast Cancer Satellite Symposium

May 20th 2022

Program chair Aditya Bardia, MD, MPH, invites you to PER®’s complimentary in-person and virtual satellite symposium.

Disability Insurance: Overview, What to Look For, Mistakes to Avoid

March 24th 2022

2022 Oncology Salary Data Report

January 21st 2022

2022 Oncology Salary Data Report

Taking a Patient-First Approach to Treatment in Chronic Lymphocytic Leukemia

September 20th 2021

As developments in treatment options advance in chronic lymphocytic leukemia, Dr Pagel discusses the importance of finding a treatment for patients to deliver long-term outcomes that do not compromise tolerability.

Minimal Residual Disease and a Treatment Option for MRD(+) CD19-Positive B-Cell Precursor Acute Lymphoblastic Leukemia

February 16th 2021